Colossal Biosciences

three living dire wolves (Romulus, Remus, Khaleesi) edited from gray wolves; mammoth program (~85 elephant-gene edits, 2028 birth target), thylacine, dodo and bluebuck programs; Colossal BioVault and World Preservation Lab for genetic-material storage.

Country
United States
Coverage
CNEUINUS
monitoring-conservation✓✓✓✓
Regulatorsusda-aphisefsamoa-china

Verifiable facts

FactValueSource
Funding$615M total raised capitalcolossal.com
Production site55,000-square-foot headquarters and laboratory in Dallas, Texascolossal.com · dmagazine.com
Production site2,000-acre ecological preserve for dire wolves at an undisclosed location in the United Statescolossal.com
CertificationAmerican Humane Certification for dire wolf facility and research protocolscolossal.com
Regulatory approvalUSDA Animal Welfare Act compliance and registrationcolossal.com
Headcount266 employees as of July 20, 2026tipranks.com
RevenueCompany started generating revenue over the last year (as of July 2026) medium confidencetechcrunch.com
Revenue$27.5M in 2024 revenue medium confidenceupmarket.co
CapacitySomatic cell nuclear transfer lab performs 200 to 300 cellular transfers per daycolossal.com · dmagazine.com

Independent sources: dmagazine.com · techcrunch.com · tipranks.com · upmarket.co

Technologies
NameClusterRisk
De-extinction & conservation biotechmonitoring-conservationMedium→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.